TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02358460

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation delivered by SLE5000 ventilator
Description: In pressure-limited ventilation arm, ventilator settings as required to maintain appropriate oxygenation and carbon-dioxide elimination.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation delivered by SLE5000 ventilator
Description: In pressure-limited ventilation arm, ventilator settings as required to maintain appropriate oxygenation and carbon-dioxide elimination.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits.
Study: NCT03260361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis, kinesitherapy, MEOPA
Description: classical intervention

Intervention type: OTHER
Group type: OTHER
Intervention: Usual practice
Description: Usual practice with treatments and physio
Study: NCT04785053

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial alternating current stimulation (tACS)
Description: The tACS intervention (gamma stimulation, theta stimulation and active sham condition) will be administered to the participants over three visits that will be completed within one of the working days (Mon-Fri) at approximately the same time of day for all participants. Participants will be randomized and blinded to the tACS treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial alternating current stimulation (tACS)
Description: The tACS intervention (gamma stimulation, theta stimulation and active sham condition) will be administered to the participants over three visits that will be completed within one of the working days (Mon-Fri) at approximately the same time of day for all participants. Participants will be randomized and blinded to the tACS treatment.
Study: NCT04207333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Arithmetic Test
Description: The researcher will call out a four-digit number and ask the participant to subtract either 7 or 13. Each minute, a new four-digit number will be called out and the participant must subtract the 7 or 13 from the number. The test will last approximately 5 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Arithmetic Test
Description: The researcher will call out a four-digit number and ask the participant to subtract either 7 or 13. Each minute, a new four-digit number will be called out and the participant must subtract the 7 or 13 from the number. The test will last approximately 5 minutes
Study: NCT03074799

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptom -based Screening(Child Contacts)
Description: Aim 1: Determine the number of child contacts per adult index case of tuberculosis to assess quality of contact tracing.~Aim 2: Determine the percentage of child contacts initiated on IPT or antituberculous therapy (ATT) and compare between intervention (symptom-based, nurse-led initiation of IPT) vs control clinics (TST-based screening with referral to hospital, current standard of care).~Aim 3: Compare outcomes of children initiated on IPT between both groups including: completion of therapy, discontinuation due to side effects, lost to follow up, and adherence while on therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical based Decisions
Description: the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT
Study: NCT01867853

Intervention type: DEVICE
Intervention: PLR
Description: passive leg raising test was done before and at the end of SBT

Intervention type: DEVICE
Intervention: PLR
Description: passive leg raising test was done before and at the end of SBT
Study: NCT01062815

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral Nutrition
Description: Parenteral Nutrition infused over 20 hours cycled with dextrose solution over 4 hours compared to Parenteral Nutrition infused continuously over 24 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Parenteral Nutrition
Description: Parenteral Nutrition infused over 20 hours cycled with dextrose solution over 4 hours compared to Parenteral Nutrition infused continuously over 24 hours.
Study: NCT01506492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM
Description: Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
Study: NCT02293343

Intervention type: OTHER
Intervention: blood profile

Intervention type: OTHER
Intervention: blood profile

Intervention type: OTHER
Intervention: blood profile
Study: NCT04534894

Intervention type: DIAGNOSTIC_TEST
Intervention: fluorescence lifetime imaging microscopy
Description: collect 2mL of venous blood and use fluorescence lifetime imaging microscopy to exam NADH fluorescence characteristics of it
Study: NCT04664660

Intervention type: OTHER
Intervention: Retrospective analysis of obstetrics outcomes
Description: Retrospective analysis of clinical records including general medical and gynecological history, pregnancy course, delivery mode and newborn conditions.

Intervention type: OTHER
Intervention: Retrospective analysis of obstetrics outcomes
Description: Retrospective analysis of clinical records including general medical and gynecological history, pregnancy course, delivery mode and newborn conditions.
Study: NCT03245476

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy focus on manual therapy and home-exercises
Description: corticoid injection + physiotherapy with a focus on manual therapy and home-exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy focus on education and supported home exercises
Description: corticosteroid injection + physiotherapy with focus on education and supported home exercises
Study: NCT03851341

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Janumet XR tablet 100/1000 mg
Description: To administrate the Janumet XR tablet

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GLH1SM tablet 100/1000 mg
Description: To administrate the GLH1SM tablet
Study: NCT02698423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cobas HPV DNA Test
Description: Women will receive a home-sent sample for HPV self-testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Papanicolau test
Description: Women will be invited to come in for a physician-performed Pap test
Study: NCT04570891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fascia iliaca compartment block
Description: Ultrasound-guided fascia iliaca compartment block (0.25% ropivacaine 1mL/kg, Max 30mL) will be provided at the end of surgery.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No regional block is provided at the end of surgery.
Study: NCT01742221

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HemaMax
Description: single subcutaneous 12 microgram dose of HemaMax

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single subcutaneous dose
Study: NCT04304222

Intervention type: DEVICE
Group type: OTHER
Intervention: 3D Printed Denture Framework
Description: The Denture Framework is 3D printed from the digital image obtained from the denture mold.

Intervention type: DEVICE
Group type: OTHER
Intervention: 3D Printed Denture Framework
Description: The Denture Framework is 3D printed from the digital image obtained from the denture mold.
Study: NCT01903434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally
Study: NCT01081210

Intervention type: OTHER
Intervention: Ultrasound examination
Description: Screening with bedside ultrasound examination
Study: NCT01471873

Intervention type: PROCEDURE
Intervention: Corneal Collagen Cross-linking (CXL)
Description: The same surgical procedure was applied to all CXLG patients that included:~Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well.
Study: NCT01717612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thrombin
Description: Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Histoacryl
Description: The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
Study: NCT00664274

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive remediation therapy
Description: 36 sessions of Computerized Cognitive Skills Training, 3 per week for 12 weeks.

Intervention type: GENETIC
Group type: OTHER
Intervention: COMT Genotyping
Description: One time saliva sample is taken to genotype catechol-O-methyltransferase Val158/108Met alleles.
Study: NCT02102061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multidisciplinary intervention
Description: a health- and quality of life-oriented program comprising exercise, nutrition advices, and philosophy meetings, without a focus on weight loss, following the philosophical principles from Health at Every Size.
Study: NCT02239094

Intervention type: DRUG
Group type: OTHER
Intervention: Lurasidone (Latuda)
Description: Antipsychotic medication approved for use with Bipolar disorder
Study: NCT03216265

Intervention type: OTHER
Group type: OTHER
Intervention: Test product (Moisturising cream)
Description: Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).

Intervention type: OTHER
Group type: OTHER
Intervention: Test product (Moisturising cream)
Description: Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).

Intervention type: OTHER
Group type: OTHER
Intervention: Positive control (Commercial market place moisturising cream)
Description: Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).

Intervention type: OTHER
Group type: OTHER
Intervention: Positive control (Commercial market place moisturising cream)
Description: Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).

Intervention type: OTHER
Group type: OTHER
Intervention: No treatment
Description: No treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: No treatment
Description: No treatment.
Study: NCT02002078

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: methylprednisolon
Study: NCT01949064

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Grindcare

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Michigan-type occlusal splint
Study: NCT03763487

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: venous blood sampling
Description: Venous blood samples to determine memory B lymphocytes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spleen volumetry
Description: Ultrasound examination of spleen to scaled the size.
Study: NCT00000451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline
Description: 16 week outpatient study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone
Description: 16 week outpatient study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone
Description: 16 week outpatient study
Study: NCT02874794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696 (sacubitril/valsartan)
Description: 24/26mg, 49/51mg and 97/103mg oral, tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: 2.5mg, 5mg, and 10mg, oral, tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Enalapril
Description: matching placebo (2.5mg, 5mg and 10mg) oral, tablets
Study: NCT01385228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel given IV on Day 1 starting dose 60mg/m2 increase to 75mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Dose Level Xb - daily administration of pazopanib on days 3 through 19 starting at 400mg with a maximum dose of 1000mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5mg Prednisone given twice daily days 1-21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5mg Prednisone given twice daily days 1-21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Study: NCT02911207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patients choose one creative activity and one physical activity
Description: taking part in 2 activities (a creative one and a physical one)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: patients choose one creative activity and one physical activity
Description: taking part in 2 activities (a creative one and a physical one)
Study: NCT03335917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: Participants will be exposed to hypoxia by reducing barometric pressure or by reducing oxygen concentration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: Participants will be exposed to hypoxia by reducing barometric pressure or by reducing oxygen concentration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Graded cycling exercise to volitional fatigue

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Graded cycling exercise to volitional fatigue

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Graded cycling exercise to volitional fatigue
Study: NCT02610959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
Study: NCT00367770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tracleer®
Description: Patients will receive up to 125 mg b.i.d. of Tracleer.
Study: NCT03843710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gold Nanocrystals
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gold Nanocrystals
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gold Nanocrystals
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gold Nanocrystals
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
Study: NCT00761150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-712
Description: ABT-712 extended-release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-712
Description: ABT-712 extended-release tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT01381146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact of Crime Modules
Description: 5 session/1 week modules of a restorative justice inspired victim impact group intervention

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TAU
Description: have access to other jail programs and services
Study: NCT01857310

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5 mg folic acid and 30 mg elemental zinc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo
Study: NCT02392845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Docetaxel (DTX) and Epirubicin (EPI)
Description: Six cycles of densified DTX+EPI chemotherapy (2 weeks per cycle) for each patient
Study: NCT02207660

Intervention type: DRUG
Intervention: Cisplatin,P-HDFL
Description: The P-HDFL regimen was given as follows: In each 21-day cycle, patients received 24-hour infusions of cisplatin at 45 or 50 mg/m2 and 5-FU 2,600mg/m2 plus leucovorin 300 mg/m2 intravenous 24-hour infusion on Day 1. Normal saline hydration (≧1000 mL), dexamethasone, and antiemetics (ondansetron or granisetron) were given prophylactically before each dose of cisplatin.
Study: NCT05039827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization with movement
Description: Heating fermentation was done for 10 minutes as baseline treatment. MWM with wrist extension was given for alternative days in a week as per 3 sessions per week for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soft Tissue Mobilization
Description: Heating fermentation was done for 10 minutes as baseline treatment. Parallel and longitudinal massage was given for alternative days in a week as per 3 sessions per week for 4 weeks
Study: NCT01216267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: lansoprazole 30 mg HS x 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lansoprazole
Description: lanzoprazole 30 mg HS for 7 days
Study: NCT04700033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatic IVR (sIVR)
Description: This intervention will consist of an IVR protocol that is focused on somatic interaction that encourages disassociation between pain and visualization and movement of the affected limbs. Subjects in this group will be exposed to an IVR environment that cycles them through a series of stretching and mobility exercises for the affected limbs bilaterally.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Distractive IVR (dIVR)
Description: This intervention will consist of an IVR that is focused on distracting the subject from the pain. Subjects in this group will be exposed to a variety of engaging landscape IVR environments, without the ability to visualize their own body.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control IVR (cIVR)
Description: This intervention will consist of an IVR exposure to a black screen for 20 minutes. No light, images or scenery will be present in the IVR and it will serve as a control condition for the trial.
Study: NCT01751802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam
Description: Antagonist of the dopamine D1 receptor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Ecopipam
Study: NCT01376531

Intervention type: PROCEDURE
Intervention: continuous veno-venous hemodialysis
Description: continuous veno-venous hemodialysis
Study: NCT02874794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of LCZ696
Description: matching placebo (24/26mg, 49/51mg and 97/103mg) oral, tablets
Study: NCT03679481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Description: Following induction of anesthesia and prior to surgical incision, patients will receive 1 gram of intravenous TXA mixed in 100cc of normal saline.
Study: NCT04568343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy
Description: We use two capsule endoscopy for evaluation their diagnostic yield. Patient will recieve different capsule endoscopy:The Endocapsule (EC-10) and CapsoCam Plus (Capsovision) capsule
Study: NCT00538265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Tacrolimus started at 0.50 mg/kg b.i.d. starting at D0, by nasogastric tube and then 1 to 2 hours before meals. The dose of tacrolimus will be adjusted as soon as possible to obtain trough concentrations of the product between 10 and 20 µg/L between D0 and 6 months and then between 8 and 15 µg/L after 6 months